#043: Why IPOs Matter + Cerebras and BitGo
Craig explains why Access IPOs is unapologetically pro-IPO and why IPOs remain the best way for retail investors to benefit from the long-term growth of innovative industries. In IPO Radar…
Craig explains why Access IPOs is unapologetically pro-IPO and why IPOs remain the best way for retail investors to benefit from the long-term growth of innovative industries. In IPO Radar…
Perplexity may be the Google Search disruptor coveted by VCs and rival tech behemoths. Follow along as Perplexity rides the AI wave to a more accurate and transparent search experience.
Harvey’s rapid path to a potential IPO reflects unusual confidence in legal AI’s winner-take-most dynamics, though its revenue multiple suggests significant repricing risk once public market scrutiny begins.
Craig highlights the 18 startups he expects to IPO in 2026. Did your favorite pre-IPO company make the list? What other companies should be on it? Monitor the Upcoming IPOs…
Explore ways to invest in OpenEvidence stock before, during, and after a future IPO—covering pre-IPO access, broker participation, valuation risks, and what retail investors should realistically expect.
Explore opportunities to invest in the Dataiku IPO, reported to be arriving in the first half of 2026. Invest in leading AI, fintech, and defense startups via Fundrise Venture. $10…
AI software gets most of the mainstream press attention. But Cerebras aims to be a premium hardware platform for AI computing, competing against NVIDIA with a different approach designing chips and processing data.
Craig reveals his 2026 IPO Wish List. These are the late-stage startups we’d love to go public, but most are probably not in 2026 (with a few exceptions, 2026 could…
Explore opportunities to invest in the Motive IPO, which is expected during the third or fourth week of January after filing on December 23rd. Read the S-1 filing below. Motive…
The SpaceX IPO may finally arrive in the second half of 2026. Craig breaks down the orbital path that go us here, latest reports, and what to expect in the…
Verkada is disrupting a legacy industry by fully integrating all its products into a cohesive cloud-based hybrid hardware and software solution. The massive addressable market has investors surveilling its IPO prospects.
Abridge’s rapid growth and strong clinical ties position it as a standout in healthcare AI, but limited share access and high valuations mean investors should track its progress carefully ahead of any future IPO.